This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech's Longer Convalescence

If biotech does rebound, it will likely come this fall when a gaggle of investment banks will be holding biotech investor conferences in September and October, per custom. The medical meeting calendar also gets busy, including important cancer-research meetings scheduled for September and December.

But compared with years passed, the back end of 2004 is not filled with as many clinical and regulatory catalysts that so often attract the attention of investors. Still, there are some potential market-moving events expected in the coming months, which include:

  • Eyetech (EYET) and Pfizer (PFE - Get Report) bringing their drug Macugen (used to treat vision loss in older people) in front of a Food and Drug Administration advisory panel on Aug. 27.
  • In late September, the FDA is expected to announce an approval decision for Gilead Sciences' (GILD - Get Report) new combination HIV pill.
  • In October, Maxim Pharmaceuticals (MAXM) is expected to release results from a phase III study of its skin cancer drug Ceplene.
  • Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback.
    3 of 3

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
    Submit an article to us!
    IMCL $3.00 -44.44%
    GILD $100.66 -0.72%
    PFE $35.01 -0.09%
    AAPL $127.60 2.28%
    FB $83.09 2.87%


    DOW 18,034.93 +208.63 1.17%
    S&P 500 2,100.40 +19.22 0.92%
    NASDAQ 4,994.6020 +62.7870 1.27%

    Partners Compare Online Brokers

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs